All News

2020

November

Media Release / Nov 24, 2020

Novartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event

Read More
Media Release / Nov 19, 2020

Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy

Read More
Media Release / Nov 19, 2020

New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases

Read More
Media Release / Nov 19, 2020

Novartis set to achieve 100% renewable electricity in its European operations

Read More
Media Release / Nov 13, 2020

Results from real-world data and post-hoc analysis of Novartis Beovu® pivotal trials presented at AAO 2020

Read More
Media Release / Nov 13, 2020

New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender

Read More
Media Release / Nov 06, 2020

Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)

Read More
Media Release / Nov 05, 2020

Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study

Read More
Media Release / Nov 02, 2020

Novartis announces positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention

Read More

October

Media Release / Oct 30, 2020

Novartis sickle cell medicine Adakveo® approved in Europe to prevent recurrent vaso-occlusive crises

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

Learn More